8-K: AirSculpt Technologies Announces Preliminary Q3 2024 Revenue, Updates Full Year Guidance

AirSculpt Technologies reported preliminary Q3 2024 revenue of approximately $42.5 million, a 9% decrease year-over-year, and updated its full-year revenue guidance to $183-$189 million while reaffirming its Adjusted EBITDA outlook.

Summary

• AirSculpt Technologies announced preliminary revenue for the third quarter of 2024, estimating approximately $42.5 million.
• This represents a decrease of about 9% compared to the same quarter last year.
• Same-store cases declined by 8.1% year-over-year, an improvement from the 14% decline in the previous quarter.
• The company has revised its full-year 2024 revenue guidance to a range of $183 million to $189 million, compared to the previous range of $180 million to $190 million.
• AirSculpt is maintaining its full-year 2024 Adjusted EBITDA outlook of $23 million to $28 million.
• Four new locations were opened in the third quarter, with a fifth center expected to open soon.
• The company will announce its full third-quarter financial results on November 8, 2024, before the market opens.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to the revenue decline and lowered guidance, although there are some positive aspects like improved same-store sales trends and new location openings. The overall tone suggests challenges ahead.

Positives

• The decline in same-store cases improved significantly from the previous quarter, moving from a 14% decline to an 8.1% decline.
• The company opened four new locations in the third quarter, expanding its reach.
• AirSculpt reaffirmed its full-year Adjusted EBITDA guidance, indicating confidence in profitability.
• The company is actively focusing on driving demand and improving lead conversion.

Negatives

• Preliminary Q3 2024 revenue decreased by approximately 9% compared to the same period last year.
• Same-store cases experienced a decline of 8.1% year-over-year.
• The company has lowered its full-year revenue guidance, indicating a potential slowdown in growth.

Risks

• The company faces macroeconomic challenges that are impacting top-line revenue.
• There is a risk that final results for the third quarter may differ materially from the preliminary estimates.
• The company is subject to risks related to opening new centers, including rising interest rates and inflation.
• Increased competition in the weight loss and obesity solutions market, including the rise of weight-loss drugs, poses a risk.
• The company faces risks related to third-party manufacturers, competition for surgeons, and potential litigation.

Future Outlook

The company expects full-year 2024 revenue to be between $183 million and $189 million and maintains its Adjusted EBITDA outlook of $23 million to $28 million. They plan to continue focusing on driving demand and improving lead conversion.

Management Comments

• Dennis Dean, Interim CEO and CFO, stated that while they continue to see top-line pressures from macroeconomic challenges, they were pleased to see improved same-store case performance compared to the second quarter.
• Management highlighted their focus on driving demand and improving lead conversion during the quarter.

Industry Context

The announcement comes amid increasing competition in the weight loss and body contouring market, particularly with the rise of new weight-loss drugs. AirSculpt is positioning itself as a premium, minimally invasive option in this competitive landscape.

Comparison to Industry Standards

• While specific competitor data is not provided in the document, the 9% year-over-year revenue decrease and 8.1% same-store case decline suggest AirSculpt is facing headwinds similar to other discretionary healthcare providers in the current economic climate.
• Companies like InMode and Cutera, which also offer aesthetic medical devices and procedures, have reported varying results, with some experiencing growth and others facing similar challenges related to consumer spending and economic uncertainty.
• The company's focus on opening new locations is a common strategy in the industry to drive growth, but the success of these new centers will be crucial for future performance.

Stakeholder Impact

• Shareholders may react negatively to the decreased revenue and lowered guidance.
• Employees may be impacted by the company's performance and future growth plans.
• Customers may be affected by the company's ability to expand and maintain service quality.
• Suppliers may be impacted by changes in the company's purchasing patterns.

Next Steps

• The company will announce its full third-quarter financial results on November 8, 2024.
• AirSculpt will conduct a conference call on November 8, 2024, to discuss the results.

Key Dates

Keywords

AirSculpt, body contouring, revenue, EBITDA, financial results, same-store sales, guidance, healthcare, cosmetic procedures